Cleveland Biolabs Inc., Roswell Park Cancer Institute Announce Publication of Studies Defining Role of Liver in Activity of Entolimod (CBLB502)

Published: May 01, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BUFFALO, N.Y., May 1, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies identifying the liver as a key mediator of Entolimod's tissue-protective and anticancer activities in Proceedings of the National Academy of Sciences of the United States of America (PNAS), the official journal of the United States National Academy of Sciences. The reported studies were conducted by scientists at Roswell Park Cancer Institute and Cleveland BioLabs (CBLI) in collaboration with researchers at Attagene, Inc. and the Gamaleya Research Institute for Epidemiology and Microbiology in Moscow.

Help employers find you! Check out all the jobs and post your resume.

Back to news